[go: up one dir, main page]

TN2018000262A1 - Substituted piperidine compound and use there of. - Google Patents

Substituted piperidine compound and use there of.

Info

Publication number
TN2018000262A1
TN2018000262A1 TNP/2018/000262A TN2018000262A TN2018000262A1 TN 2018000262 A1 TN2018000262 A1 TN 2018000262A1 TN 2018000262 A TN2018000262 A TN 2018000262A TN 2018000262 A1 TN2018000262 A1 TN 2018000262A1
Authority
TN
Tunisia
Prior art keywords
substituted piperidine
piperidine compound
receptor agonist
agonist activity
orexin type
Prior art date
Application number
TNP/2018/000262A
Other languages
English (en)
Inventor
Tatsuhiko Fujimoto
Koichiro Fukuda
Mariko HIROZANE
Takahiro Matsumoto
Kentaro Rikimaru
Hiromichi Sugimoto
Norihito Tokunaga
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of TN2018000262A1 publication Critical patent/TN2018000262A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
TNP/2018/000262A 2016-02-04 2017-02-01 Substituted piperidine compound and use there of. TN2018000262A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016019834 2016-02-04
PCT/JP2017/003610 WO2017135306A1 (en) 2016-02-04 2017-02-01 Substituted piperidine compound and use thereof

Publications (1)

Publication Number Publication Date
TN2018000262A1 true TN2018000262A1 (en) 2020-01-16

Family

ID=58054473

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP/2018/000262A TN2018000262A1 (en) 2016-02-04 2017-02-01 Substituted piperidine compound and use there of.

Country Status (36)

Country Link
US (6) US10508083B2 (fi)
EP (3) EP4438041A3 (fi)
JP (1) JP6609060B2 (fi)
KR (1) KR102734774B1 (fi)
CN (2) CN114181136A (fi)
AR (1) AR107519A1 (fi)
AU (1) AU2017215021B2 (fi)
BR (1) BR112018015574B1 (fi)
CA (1) CA3013428C (fi)
CL (1) CL2018002099A1 (fi)
CO (1) CO2018008705A2 (fi)
CY (1) CY1125003T1 (fi)
DK (2) DK3411358T3 (fi)
EA (1) EA036166B1 (fi)
EC (1) ECSP18066504A (fi)
ES (2) ES2991028T3 (fi)
FI (1) FI3984994T3 (fi)
HR (2) HRP20241334T1 (fi)
HU (2) HUE057696T2 (fi)
IL (1) IL260835B (fi)
LT (2) LT3411358T (fi)
MA (1) MA43963A (fi)
MX (1) MX382435B (fi)
MY (1) MY186905A (fi)
PH (1) PH12018501666B1 (fi)
PL (2) PL3411358T3 (fi)
PT (2) PT3984994T (fi)
RS (2) RS62861B1 (fi)
SG (1) SG11201806429PA (fi)
SI (2) SI3411358T1 (fi)
TN (1) TN2018000262A1 (fi)
TW (2) TWI755374B (fi)
UA (1) UA122433C2 (fi)
UY (1) UY37103A (fi)
WO (1) WO2017135306A1 (fi)
ZA (1) ZA201805544B (fi)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3411358T3 (pl) 2016-02-04 2022-02-28 Takeda Pharmaceutical Company Limited Podstawiony związek piperydynowy i jego zastosowanie
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
EP3594203B1 (en) 2017-03-08 2021-08-04 Takeda Pharmaceutical Company Limited Substituted pyrrolidine compound and use thereof
JP7012703B2 (ja) 2017-03-08 2022-02-14 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
BR112020000823A2 (pt) 2017-08-03 2020-07-21 Takeda Pharmaceutical Company Limited composto, medicamento, métodos para ativar um receptor de orexina tipo 2 e para profilaxia ou tratamento de narcolepsia, e, uso de um composto ou sal.
JP7189140B2 (ja) * 2017-08-03 2022-12-13 武田薬品工業株式会社 複素環化合物およびその用途
WO2019117148A1 (ja) 2017-12-12 2019-06-20 国立大学法人 筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
EA202192934A1 (ru) * 2017-12-25 2022-02-09 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение и его применение
EP3816154B1 (en) * 2018-06-29 2025-04-23 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
EP3816153B1 (en) * 2018-06-29 2023-10-18 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JP7408569B2 (ja) * 2018-12-12 2024-01-05 武田薬品工業株式会社 複素環化合物
JP7379374B2 (ja) * 2018-12-12 2023-11-14 武田薬品工業株式会社 複素環化合物
US11028048B2 (en) * 2019-01-31 2021-06-08 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2020167706A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
US12331018B2 (en) 2019-02-13 2025-06-17 Merck Sharp & Dohme Llc Pyrrolidine orexin receptor agonists
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
WO2021048821A1 (en) 2019-09-13 2021-03-18 Takeda Pharmaceutical Company Limited Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness
MX2022003018A (es) * 2019-09-13 2022-06-14 Takeda Pharmaceuticals Co Danavorexton (tak-925) para usarse en el tratamiento de la narcolepsia.
EP4628167A3 (en) * 2019-11-25 2025-12-03 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
WO2021106975A1 (ja) 2019-11-27 2021-06-03 武田薬品工業株式会社 複素環化合物
JP7739180B2 (ja) * 2019-11-27 2025-09-16 住友ファーマ株式会社 シクロアルキルウレア誘導体
US11352357B2 (en) 2019-11-27 2022-06-07 Sumitomo Dainippon Pharma Co., Ltd. Cycloalkylurea derivative
CN115226390A (zh) * 2020-01-10 2022-10-21 武田药品工业株式会社 使用细胞色素p450的抑制剂增强3-((甲基磺酰基)氨基)-2-(((4-苯基环己基)氧基)甲基)哌啶-1-羧酸甲酯或其盐的药代动力学或增加其血浆浓度的方法
EP4199925A4 (en) * 2020-08-18 2024-08-28 Merck Sharp & Dohme LLC CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS
CR20230089A (es) 2020-08-18 2023-04-11 Merck Sharp & Dohme Llc Agonistas de bicicloheptano pirrolidina de los receptores de orexina
JP2022064180A (ja) * 2020-10-13 2022-04-25 武田薬品工業株式会社 複素環化合物
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
WO2022109117A1 (en) * 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. 3-amino pyrrolidine and piperidine macrocyclic orexin receptor agonists
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
US12006330B2 (en) * 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
WO2022190060A1 (en) 2021-03-12 2022-09-15 Takeda Pharmaceutical Company Limited An orexin 2 receptor agonist for the treatment of an orexin-mediated disease or disorder
CA3215906A1 (en) 2021-04-02 2022-10-06 Takeda Pharmaceutical Company Limited Use of an orexin 2 receptor agonist for post operation recovery
CA3215210A1 (en) 2021-04-26 2022-11-03 Younggi Choi Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
TW202309051A (zh) * 2021-05-03 2023-03-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 食慾素受體促效劑及其用途
CA3219506A1 (en) 2021-05-26 2022-12-01 Hoan Huynh Substituted fused bicyclic macrocyclic compounds and related methods of treatment
JP7668768B2 (ja) * 2021-05-26 2025-04-25 住友ファーマ株式会社 シクロアルキルウレア誘導体を含有する医薬組成物
JP2024520396A (ja) 2021-05-26 2024-05-24 アルカーメス，インコーポレイテッド 置換されるカルバメート大環状化合物および関連のある治療方法
CN117561238A (zh) 2021-05-26 2024-02-13 住友制药株式会社 苯基脲衍生物
WO2023199091A1 (en) 2022-04-12 2023-10-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
CA3248959A1 (en) 2022-04-22 2025-02-03 Sumitomo Pharma Co Ltd BICYCLOAMINE CARBOXAMIDE DERIVATIVE
CN119730850A (zh) * 2022-06-21 2025-03-28 阿尔克姆斯有限公司 取代的稠合二环化合物以及相关的治疗方法
AU2023288422A1 (en) * 2022-06-21 2025-01-09 Alkermes, Inc. Substituted fused bicyclic compounds and related methods of treatment
CN119730843A (zh) * 2022-06-21 2025-03-28 阿尔克姆斯有限公司 取代的吡咯烷基和哌啶基化合物以及相关的治疗方法
TW202423404A (zh) 2022-10-07 2024-06-16 日商橘生藥品工業股份有限公司 環戊烷化合物
AU2023375094A1 (en) 2022-10-31 2025-05-08 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP4611745A1 (en) 2022-10-31 2025-09-10 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists
AU2023403030A1 (en) 2022-11-30 2025-06-05 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
TW202430169A (zh) 2022-12-16 2024-08-01 日商第一三共股份有限公司 2-氮雜雙環[3.1.1]庚烷化合物
US20240309016A1 (en) 2023-03-16 2024-09-19 Takeda Pharmaceutical Company Limited Macrocyclic heterocycle compounds and use thereof
WO2024246867A1 (en) * 2023-06-02 2024-12-05 Takeda Pharmaceutical Company Limited Use of an orexin 2 receptor agonist for improving respiratory function during sleep
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists
WO2025211415A1 (ja) * 2024-04-04 2025-10-09 キッセイ薬品工業株式会社 置換スルホンアミド化合物
WO2025211416A1 (ja) * 2024-04-04 2025-10-09 キッセイ薬品工業株式会社 置換スルホンアミド大環状化合物
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
WO2025229493A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists
WO2025229494A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2025229495A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2025229492A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Orexin type 2 receptor agonist microcapsules for sustained release dosing

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2608602A1 (fr) 1986-12-23 1988-06-24 Cerm Cent Europ Rech Mauvernay Nouvelles 3-piperidineamines ou 3-azepineamines substituees, leur preparation et leurs applications en therapeutique
SE9003652D0 (sv) 1990-11-15 1990-11-15 Astra Ab New heterocyclic compounds
EP0815134B1 (en) 1995-03-14 2002-06-05 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
JP4326024B2 (ja) 1996-03-15 2009-09-02 ノバルティス アクチエンゲゼルシャフト 新規なＮ―７―ヘテロサイクリル―ピロロ［２，３―ｄ］ピリミジンおよびこれらの使用
DE69733655T2 (de) 1996-08-27 2006-04-27 Praecis Pharmaceuticals, Inc., Cambridge beta-AMYLOID PEPTIDAGGREGATION REGULIERENDE PEPTIDE MIT D-AMINOSÄUREN
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
US6750344B1 (en) 1997-09-05 2004-06-15 Isis Pharmaceuticals, Inc. Amine compounds and combinatorial libraries comprising same
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
DE60045005D1 (de) 1999-06-28 2010-11-04 Oklahoma Med Res Found Inhibitoren des memapsin 2 und ihre verwendung
WO2001008720A2 (en) 1999-07-30 2001-02-08 The Board Of Trustees Of The Leland Stanford Junior University Hypocretin and hypocretin receptors in regulation of sleep and related disorders
WO2001074162A1 (en) 2000-04-04 2001-10-11 The Regents Of The University Of California Treatment of sleep disorders with hypocretin-1
EP1581648A2 (en) 2002-09-09 2005-10-05 Nura, Inc. G protein coupled receptors and uses thereof
EP1572133B1 (en) 2002-12-13 2008-04-09 Janssen Pharmaceutica N.V. Method for identifying modulators of human orexin-2 receptor
US20110053859A1 (en) 2007-10-10 2011-03-03 The U. S. Government Respresented by the Department of Veterans Affairs Methods to reduce the effects of sleep deprivation
US8258163B2 (en) 2008-06-04 2012-09-04 Board Of Regents, The University Of Texas System Small-molecule agonists for type-2 orexin receptor
WO2011119541A1 (en) 2010-03-26 2011-09-29 Schering Corporation Novel spiro imidazolone derivatives as glucagon receptor antagonists, compositions, and methods for their use
US9527807B2 (en) * 2011-04-05 2016-12-27 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
WO2013011098A1 (en) 2011-07-20 2013-01-24 Universite Pierre Et Marie Curie (Paris 6) Imino-sugar c-glycosides, preparation and use thereof
WO2014006402A1 (en) * 2012-07-03 2014-01-09 Heptares Therapeutics Limited Orexin receptor antagonists
WO2014170343A1 (en) 2013-04-15 2014-10-23 Icm (Institut Du Cerveau Et De La Moelle Épinière) Depolarizing agents and nicotinic acetylcholine receptor modulators for treating dopaminergic-related disorders
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
US20160250224A1 (en) 2013-09-24 2016-09-01 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
EP3068783B1 (en) 2013-11-15 2020-09-23 The Board of Trustees of the Leland Stanford Junior University Agonists of hypocretin receptor 2 for use for treating heart failure
CN106029633A (zh) 2013-12-12 2016-10-12 国立大学法人筑波大学 磺酰胺衍生物或其药学上可接受的酸加成盐
SG10201900536TA (en) 2014-03-06 2019-02-27 Shanghai Haiyan Pharmaceutical Tech Co Ltd Piperidine derivatives as orexin receptor antagonist
JP6552117B2 (ja) 2014-03-28 2019-07-31 国立大学法人 筑波大学 敗血症の予防治療剤
EP3029024A1 (en) 2014-12-02 2016-06-08 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
JP6746107B2 (ja) 2015-02-19 2020-08-26 国立大学法人 筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
JP6189905B2 (ja) 2015-09-30 2017-08-30 株式会社スクウェア・エニックス ビデオゲーム処理プログラム、及びビデオゲーム処理システム
PL3411358T3 (pl) 2016-02-04 2022-02-28 Takeda Pharmaceutical Company Limited Podstawiony związek piperydynowy i jego zastosowanie

Also Published As

Publication number Publication date
MY186905A (en) 2021-08-26
ES2991028T3 (es) 2024-12-02
PL3984994T3 (pl) 2024-11-04
AU2017215021A1 (en) 2018-08-30
UY37103A (es) 2017-08-31
PT3984994T (pt) 2024-10-10
CN108884043A (zh) 2018-11-23
EP4438041A2 (en) 2024-10-02
WO2017135306A1 (en) 2017-08-10
RS62861B1 (sr) 2022-02-28
BR112018015574B1 (pt) 2023-11-28
US12281073B2 (en) 2025-04-22
CL2018002099A1 (es) 2018-11-09
PH12018501666B1 (en) 2023-05-26
SI3984994T1 (sl) 2024-12-31
US20190263843A1 (en) 2019-08-29
PH12018501666A1 (en) 2019-06-17
EP3411358A1 (en) 2018-12-12
JP6609060B2 (ja) 2019-11-20
US11292766B2 (en) 2022-04-05
IL260835A (en) 2019-02-28
UA122433C2 (uk) 2020-11-10
US20240174610A1 (en) 2024-05-30
EP4438041A3 (en) 2025-01-01
US10898737B2 (en) 2021-01-26
MA43963A (fr) 2018-12-12
CY1125003T1 (el) 2023-01-05
DK3984994T3 (da) 2024-10-14
KR20180103985A (ko) 2018-09-19
EA201891742A1 (ru) 2019-01-31
NZ745259A (en) 2025-03-28
US20220081399A1 (en) 2022-03-17
JP2019504098A (ja) 2019-02-14
ECSP18066504A (es) 2018-10-31
SG11201806429PA (en) 2018-08-30
LT3984994T (lt) 2024-10-10
HRP20241334T1 (hr) 2025-01-03
AU2017215021B2 (en) 2020-07-23
MX2018009494A (es) 2018-09-06
HUE068362T2 (hu) 2024-12-28
HRP20220127T1 (hr) 2022-04-15
FI3984994T3 (fi) 2024-10-03
US10287305B2 (en) 2019-05-14
EP3411358B1 (en) 2021-11-24
DK3411358T3 (da) 2022-01-17
EP3984994A1 (en) 2022-04-20
CA3013428C (en) 2024-02-13
LT3411358T (lt) 2022-04-25
CN114181136A (zh) 2022-03-15
ZA201805544B (en) 2019-11-27
US20190031611A1 (en) 2019-01-31
HUE057696T2 (hu) 2022-05-28
TW201731817A (zh) 2017-09-16
EA036166B1 (ru) 2020-10-08
KR102734774B1 (ko) 2024-11-26
MX382435B (es) 2025-03-13
IL260835B (en) 2021-10-31
BR112018015574A2 (pt) 2018-12-26
CA3013428A1 (en) 2017-08-10
RS65984B1 (sr) 2024-10-31
SI3411358T1 (sl) 2022-04-29
EP3984994B1 (en) 2024-07-03
US20200115399A1 (en) 2020-04-16
US10508083B2 (en) 2019-12-17
TWI755374B (zh) 2022-02-21
US20170226137A1 (en) 2017-08-10
CO2018008705A2 (es) 2018-11-13
PT3411358T (pt) 2022-01-19
AR107519A1 (es) 2018-05-09
TW202220959A (zh) 2022-06-01
CN108884043B (zh) 2021-11-26
PL3411358T3 (pl) 2022-02-28
ES2907373T3 (es) 2022-04-25

Similar Documents

Publication Publication Date Title
TN2018000262A1 (en) Substituted piperidine compound and use there of.
MY202221A (en) Heterocyclic compound and use thereof
MY209784A (en) Heterocyclic compound and use thereof
PH12016502574A1 (en) Heterocyclic compounds and their use as retinoid-related orphan receptor (ror) gamma-t inhibitors
PH12016501813A1 (en) 1,3-benzodioxole derivative
JOP20170192A1 (ar) داي نوكليوتيد حلقي
PH12016500467B1 (en) Aminoheteroarlyl benzamides as kinase inhibitors
MX351513B (es) Compuesto de alquinilbenceno 3,5-disustituido y sales del mismo.
SG10201805628TA (en) Deuterated heterocyclic compounds and their use as imaging agents
IN2015DN01035A (fi)
GEP20186876B (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
PH12019502248A1 (en) Ip6k inhibitors
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
MY162886A (en) Novel tetrahydropyridopyrimidine compound or salt thereof
MX2020006436A (es) Compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
MX2020006434A (es) Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
MX2017005422A (es) Inhibidores de histona desacetilasa y sus usos en terapia.
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
MX2017002015A (es) Ligando del receptor 2 de canabinoide radiomarcado.
PH12019500492A1 (en) Imide compound and use thereof
MX2019007786A (es) Compuestos sustituidos de guanidina.
EA202090428A1 (ru) Гетероциклическое соединение и его применение
UA107885U (uk) Застосування вінборону для профілактики гастропатії, індукованої ібупрофеном
UA107468U (uk) 25,27-ди-(5-тіо-октилокси)калікс[4]арен-краун-6
UA86566U (en) N-hydroxyhomoazaadamantanone and dioxomolybdenum complex thereof